Jiang Yiwei (Eve Jiang), corporate vice president (CVP) of Novo Nordisk’s (NYSE: NVO) Emerging Business Division (EBD), is leaving the company to pursue external opportunities, with her last day set for March 3. Dr. Christine Zhou Xia Ping, Novo’s senior vice president and president of Region China, will assume the interim role until a successor is appointed.
Career Highlights at Novo Nordisk
During her six-year tenure at Novo Nordisk, Eve Jiang held several key positions, including senior marketing director for Insulin and general manager of Novo Nordisk Hong Kong. She made significant contributions to the company, including promoting the Tresiba boost plan and overseeing the world-class launch of Ryzodeg. Additionally, she played a crucial role in preparing the company for insulin volume-based procurement (VBP) in China.
Transition and Future Outlook
Eve Jiang’s departure marks the end of a notable career at Novo Nordisk, where she contributed to several strategic initiatives. Dr. Christine Zhou will step into the interim role, leveraging her extensive experience to ensure a smooth transition and continued growth for the EBD.-Fineline Info & Tech
Leave a Reply